Compare iShares MSCI Hong Kong ETF (EWH) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? iShares MSCI Hong Kong ETF trades at $21.92 (market cap $1.19B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 7.1× iShares MSCI Hong Kong ETF's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 63 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EWH | HNGE | |
|---|---|---|
Market Cap | $1.19B | $8.48B |
Volume | 2,118,222 | 879,799 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $105.14 |
52-Week Low | $20.92 | $31.17 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | — | $8.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.35 with a 1.78% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance cluster tightly around $22.
The outlook remains cautious given Hong Kong's market volatility and geopolitical risks. Investment opportunity exists for contrarian bets on Chinese tech recovery, but risks include sustained Fed tightening and regional tensions. Wall Street sentiment is divided, with some seeing value in oversold conditions while others warn of further downside.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
